NNVCNYSEPharmaceutical PreparationsFiscal year ends June 30

NANOVIRICIDES, INC.

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 28, 2026

$1.30−0.08 (-5.80%)

Close on Oct 19, 2026

Market cap: $28.93M
P/E (TTM): –
Dividend yield: –

NANOVIRICIDES, INC. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-06-30	FY 2025 2025-06-30	FY 2024 2024-06-30	FY 2023 2023-06-30	FY 2022 2022-06-30	FY 2021 2021-06-30	FY 2020 2020-06-30	FY 2019 2019-06-30	FY 2018 2018-06-30	FY 2017 2017-06-30	FY 2016 2016-06-30	FY 2015 2015-06-30	FY 2014 2014-06-30	FY 2013 2013-06-30	FY 2012 2012-06-30	FY 2011 2011-06-30	FY 2010 2010-06-30	FY 2009 2009-06-30	FY 2008 2008-06-30	FY 2007 2007-06-30
Revenue	0	0	0	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Research & Development	4.71	5.55	5.44	6.39	5.78	6.11	4.70	5.92	5.91	6.57	5.03	3.66	5.13	4.29	4.27	4.16	3.37	–	–	–
General & Administrative	3.60	4.04	3.08	2.55	2.33	2.63	3.30	2.74	3.41	3.03	3.83	3.40	3.54	2.30	1.82	2.27	1.74	–	–	–
Operating Expenses	8.31	9.59	8.52	8.94	8.11	8.74	8.00	8.66	9.33	9.60	8.86	7.06	8.67	6.59	6.08	6.43	4.94	–	–	–
Operating Income	-8.31	-9.59	-8.52	-8.94	-8.11	-8.74	-8.00	-8.66	-9.33	-9.60	-8.86	-7.06	-8.67	-6.59	-6.08	-6.43	-4.94	–	–	–
Interest Expense	–	0.00	0.05	0.00	0.01	0.09	0.09	0	0.19	0.78	1.04	2.65	3.09	0.96	0	0	–	–	–	–
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	–	0.16	0.17	0.06	0.05	0.01	0.00	–	–	–
Other Non-Operating Income	0.09	0.12	0.22	0.35	0.01	-0.08	-5.45	0.24	0.76	-0.70	-1.87	4.86	-4.93	-2.29	-0.13	-0.05	0.20	–	–	–
Gain (Loss) on Sale of Assets	0	–	–	–	0	0.00	0	0	–	–	–	–	–	–	–	–	–	–	–	–
Pretax Income	-8.22	–	–	–	-8.11	-8.82	-13	-8.42	-8.56	-10	-11	-2.20	-14	-8.88	-6.21	-6.48	-4.74	–	–	–
Income Tax Expense	–	–	–	–	–	–	0	0	0	0	0	0	0	0	0	0	0	–	–	–
Net Income incl. Noncontrolling Interests	-8.22	-9.47	-8.29	-8.59	-8.11	-8.82	-13	-8.42	-8.56	-10	–	–	–	–	–	–	–	–	–	–
Net Income	-8.22	-9.47	-8.29	-8.59	-8.11	-8.82	-13	-8.42	-8.56	-10	-11	-2.20	-14	-8.88	-6.21	-6.48	-4.74	-2.79	-2.74	-3.12
Net Income to Common	–	–	–	–	–	–	–	–	-8.56	-10	-11	-2.20	-14	-8.88	–	–	–	–	–	–
EPS (Basic)(per share)	-0.41	-0.63	-0.70	-0.74	-0.70	-0.81	-2.39	-2.35	-2.64	-3.40	-3.80	-0.80	-5.40	-3.80	-3.00	-3.20	-2.80	–	–	–
EPS (Diluted)(per share)	-0.41	-0.63	-0.70	-0.74	-0.70	-0.81	-2.39	-2.35	-2.64	-3.40	-3.80	-1.80	-5.40	-3.80	-3.00	-3.20	-2.80	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	20	15	12	12	12	11	5.62	3.59	3.25	3.01	2.88	2.83	2.56	2.29	2.14	1.99	1.86	–	–	–
Shares Outstanding (Diluted, Weighted)(shares)	20	15	12	12	12	11	5.62	3.59	3.25	3.01	2.88	2.96	2.56	2.38	2.14	1.99	1.86	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2026: -101.5%

Financial strength

Current ratio: 2.66
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 234.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 3.33
Dividend yield: –